How to deal with steroids use in the management of metastatic prostate cancer during pandemic

M. Baboudjian, G. Ploussard, S. Shariat, P. Ost, A. Briganti, M. Roupret, B. Pradere,

2021

https://doi.org/10.21037/tau-20-1011

Цитирование

Об авторах

M. Baboudjian
Department of Urology and Kidney Transplantation, Aix-Marseille University, Conception Academic Hospital, Aphm, Marseille, France
G. Ploussard
Department of Urology, Clinique la Croix du Sud, Quint-Fonsegrives, France
S. Shariat
Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
P. Ost
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russian Federation
A. Briganti
Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium
M. Roupret
Urological Research Institute, Department of Oncology/Unit of Urology, Irccs Ospedale San Raffaele, Milan, Italy
B. Pradere
Department of Urology, Sorbonne University, Pitié-Salpêtrière Hospital, AP-HP, Predictive Onco-urology, GRC n°5, Paris, France

Название журнала

Том

Выпуск

Страницы

Ключевые слова

abiraterone acetate; androgen receptor; apalutamide; enzalutamide; immunoglobulin G; nonsteroid antiinflammatory agent; prednisolone; prostate specific antigen; steroid; coronavirus disease 2019; Editorial; health care access; immune response; prevalence; prostate cancer; risk factor

Издатель

Тип документа

Тип лицензии Creative Commons

Правовой статус документа

Источник